title: Use of small-bore vs large-bore chest tubes for treatment of malignant pleural effusions.
abstract: OBJECTIVE
  To evaluate the efficacy of small-bore (12 French vanSonnenberg) catheters compared with standard large-bore chest tubes in the drainage and sclerotherapy of malignant pleural effusions.
  
  
  METHODS
  Retrospective review.
  
  
  METHODS
  An academic tertiary care hospital.
  
  
  METHODS
  Adult patients with documented neoplasms and malignant pleural effusions, treated between 1986 and 1995.
  
  
  METHODS
  All patients included in the study underwent drainage of malignant pleural effusions either by large-bore chest tube or by ultrasound-guided small-bore catheter. After drainage, pleurodesis was performed.
  
  
  RESULTS
  Outcome as defined by recurrence of effusion was determined by blinded examination of all postpleurodesis chest radiographs. We identified 58 cases of malignant pleural effusion in which small-bore catheters were used and 44 in which large-bore chest tubes were used. The majority of patients had breast (n = 56, 55%) or lung cancer (n = 29, 28%). The median age was 65 years. Fifty-nine patients were actively being treated with chemotherapy at the time of pleurodesis. The following sclerosing agents were used: talc, 27 (26%); tetracycline, 72 (70%); bleomycin, 2 (2%); and interferon, 1 (1%). Actuarial probabilities of recurrence at 6 weeks and 4 months were 45% and 53% for the small tubes vs 45% and 51% for the large tubes. Univariate and multivariate analyses failed to demonstrate that tube size had any influence on the rate of recurrence.
  
  
  CONCLUSIONS
  We were unable to detect any major differences in outcomes with the use of either size of chest tube. Our study suggests that small-bore catheters may be effective in the treatment of malignant pleural effusions and deserve further evaluation in prospectively designed trials.
authors.affiliation: National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston ON. wparulekar@ctg.queensu.ca
authors.forename: W
authors.initials: W
authors.lastname: Parulekar
authors.forename: G
authors.initials: G
authors.lastname: Di Primio
authors.forename: F
authors.initials: F
authors.lastname: Matzinger
authors.forename: C
authors.initials: C
authors.lastname: Dennie
authors.forename: G
authors.initials: G
authors.lastname: Bociek
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001761:Bleomycin; D001943:Breast Neoplasms / Q000150:complications; D015505:Chest Tubes / Q000009:adverse effects; D004322:Drainage / Q000009:adverse effects / Q000295:instrumentation*; D005260:Female; D006801:Humans; D007370:Interferon Type I; D008175:Lung Neoplasms / Q000150:complications; D008297:Male; D008875:Middle Aged; D016066:Pleural Effusion, Malignant / Q000401:mortality / Q000628:therapy*; D018700:Pleurodesis; D011336:Probability; D012008:Recurrence; D012189:Retrospective Studies; D012597:Sclerosing Solutions; D015911:Sclerotherapy / Q000009:adverse effects; D015996:Survival Rate; D013627:Talc; D013752:Tetracycline
chemical_list: D007370:Interferon Type I; D012597:Sclerosing Solutions; D001761:Bleomycin; D013627:Talc; D013752:Tetracycline